Generic drugmaker Teva makes $40 billion offer for rival Mylan
TEL AVIV/NEW YORK (Reuters) - Teva Pharmaceutical Industries Ltd on Tuesday made an unsolicited $40 billion offer for smaller rival Mylan NV, a bold bid for growth as its lucrative Copaxone drug faces generic competition. (Source: Reuters: Health)
Source: Reuters: Health - April 21, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Teva shares slide on generic Copaxone fears
TEL AVIV (Reuters) - Teva Pharmaceutical Industries shares slid five percent on Sunday after U.S. regulators approved a generic version of its top-selling multiple sclerosis drug and amid reports it was mulling a bid for rival Mylan. (Source: Reuters: Health)
Source: Reuters: Health - April 19, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Generic Version of Copaxone, Multiple Sclerosis Drug, Is Approved
Ten drugs are now approved to treat multiple sclerosis but none of them has had a generic equivalent. It is possible that the introduction of the generic Copaxone could help keep prices of all the drugs in check. (Source: NYT Health)
Source: NYT Health - April 16, 2015 Category: Consumer Health News Authors: ANDREW POLLACK Tags: Drugs (Pharmaceuticals) Sandoz International GmbH Food and Drug Administration Teva Pharmaceutical Industries Ltd TEVA NASDAQ Novartis AG NVS NYSE Momenta Pharmaceuticals Inc MNTA NASDAQ Multiple Sclerosis Generic Brands and Products Mylan Source Type: news
FDA Approves First Generic Copaxone in Multiple SclerosisFDA Approves First Generic Copaxone in Multiple Sclerosis
A generic version of the standard MS therapy glatiramer acetate receives FDA approval. FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 16, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Sandoz Grabs FDA Approval for Generic of Teva's Copaxone
The FDA has approved the first generic version of Teva's top branded product, multiple sclerosis drug Copaxone. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 16, 2015 Category: Pharmaceuticals Source Type: news
FDA Greenlights First Copaxone Generic
(MedPage Today) -- FDA approves generic glatiramer acetate despite efforts by Teva to stave off competition. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 16, 2015 Category: American Health Source Type: news
Generic Copaxone Approved for Multiple Sclerosis
Autoimmune disease affects central nervous systemSource: HealthDay
Related MedlinePlus Pages: Medicines, Multiple Sclerosis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 16, 2015 Category: Consumer Health News Source Type: news
FDA approves first generic Copaxone to treat multiple sclerosis
The U.S. Food and Drug Administration today approved the first generic version of Copaxone (glatiramer acetate injection), used to treat patients with relapsing forms of multiple sclerosis (MS). (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 16, 2015 Category: American Health Source Type: news
Generic Copaxone approved in US
The FDA - the US drug regulator - has approved Glatopa, a generic version of glatiramer acetate, taken as a daily injection. The drug is unlikely to be marketed in the US until later in the year.
FDA
MedPage Today
Glatiramer acetate - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 15, 2015 Category: Neurology Source Type: news
Positive interim results from major UK study on MS drugs
Results of the analysis of the 6 year data of the Department of Health (DH) MS Risk-sharing Scheme (RSS), published in the Lancet Neurology today, show that the disease modifying drugs Avonex, Betaferon, Copaxone and Rebif are cost effective and are clinically effective in reducing the progression of the disease in people with relapsing remitting multiple sclerosis (MS). (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 1, 2015 Category: Neurology Source Type: news
Setback to Natco pharma; US Supreme Court sends Teva patent case to Federal Circuit
The US Supreme Court has sent back the patent case related to Teva's multiple sclerosis drug Copaxone for a review by the Federal Circuit. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 22, 2015 Category: Pharmaceuticals Source Type: news
Supreme Court Sides with Teva on Drug Patent
The U.S. Supreme Court ruled that Teva Pharmaceutical Industries still has patent protection for top-selling multiple sclerosis drug Copaxone. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 21, 2015 Category: Pharmaceuticals Source Type: news
Supreme Court sides with Teva in MS drug patent dispute
The U.S. Supreme Court reversed a lower court ruling that had invalidated a patent held by Teva Pharmaceuticals for its multiple sclerosis drug Copaxone.
Teva (NYSE: TEVA) has spent several years in court attempting to fend off generic competition for Copaxone, which generates annual sales of about $4 billion for the company. The company is based in Israel and has its U.S. headquarters in North Wales, Pa.
Copaxone is approved for use in reducing the frequency of relapses in patients with the relapsing… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 20, 2015 Category: Biotechnology Authors: John George Source Type: news
Supreme Court rules for Teva over MS drug patent
WASHINGTON (Reuters) - The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. (Source: Reuters: Health)
Source: Reuters: Health - January 20, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Beta interferon and Copaxone relapse rates similar
A study has found that over 10 years the relapse rate for people on glatiramer acetate or beta interferon is similar.
MS Discovery Forum
Disease modifying drugs for relapsing remitting MS - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - January 20, 2015 Category: Neurology Source Type: news
